Search

Your search keyword '"M. Andreoni"' showing total 305 results
Start Over Author "M. Andreoni" Publication Year Range Last 10 years
305 results on '"M. Andreoni"'

1. Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE

Author

A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, V. Esposito, M. A. Carleo, S. Rusconi, A. Cascio, E. Manzillo, M. Andreoni, G. Orofino, A. Cappuccio, L. Reale, M. G. Marini, D. Mancusi, R. Termini, A. Uglietti, and M. Portaro

Subjects
Medicine, Science
Abstract

Abstract Antiretroviral therapy (ART) significantly reduced Human Immunodeficiency Virus (HIV) morbidity and mortality; nevertheless, stigma still characterises the living with this condition. This study explored patients’ coping experience by integrating narrative medicine (NM) in a non-interventional clinical trial. From June 2018 to September 2020 the study involved 18 centres across Italy; enrolled patients were both D/C/F/TAF naïve and previously ART-treated. Narratives were collected at enrolment (V1) and last visit (V4) and then independently analysed by three NM specialist researchers through content analysis. One-hundred and fourteen patients completed both V1 and V4 narratives. Supportive relationships with clinicians and undetectable viral load facilitated coping. Conversely, lack of disclosure of HIV-positive status, HIV metaphors, and unwillingness to narrate the life before the diagnosis indicated internalised stigma. This is the first non-interventional study to include narratives as patient reported outcomes (PROs). Improving HIV awareness and reducing the sense of guilt experienced by patients helps to overcome stigma and foster coping.

Published
2023
Full Text
View/download PDF

2. Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma

Author

M. Cecilia Martins-Costa, Rui M. B. Maciel, Teresa S. Kasamatsu, Claudia C. D. Nakabashi, Cleber P. Camacho, Felipe Crispim, Elza S. Ikejiri, M. Conceição O. Mamone, Danielle M. Andreoni, and Rosa Paula M. Biscolla

Subjects
Fine needle aspiration biopsy, anti-thyroglobulin antibody, thyroglobulin, papillary thyroid cancer, neck lymph nodes, Medicine, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

ABSTRACT Objectives The presence of thyroglobulin (Tg) in needle washouts of fine needle aspiration biopsy (Tg-FNAB) in neck lymph nodes (LNs) suspected of metastasis has become a cornerstone in the follow-up of patients with papillary thyroid carcinoma (PTC). However, there are limited data regarding the measurement of anti-Tg antibodies in these washouts (TgAb-FNAB), and it is not clear whether these antibodies interfere with the assessment of Tg-FNAB or whether there are other factors that would more consistently justify the finding of low Tg-FNAB in metastatic LNs. Materials and methods We investigated 232 FNAB samples obtained from suspicious neck LNs of 144 PTC patients. These samples were divided according to the patient’s serum TgAb status: sTgAb- (n = 203 samples) and sTgAb+ (n = 29). The TgAb-FNAB levels were measured using two different assays. Tg-FNAB was also measured using two assays when low levels (< 10 ng/mL) were identified in the first assay of the metastatic LNs from the sTgAb+ samples. Results The TgAb-FNAB results were negative in both assays in all samples. Low levels of Tg-FNAB were identified in 11/16 of the metastatic LNs of the sTgAb+ patients and 16/63 of the sTgAb- patients (p < 0.05) using assay 1. The measurement of the Tg-FNAB levels using assay 2 indicated additional metastases in 5 LNs of the sTgAb+ patients. Conclusions Factors other than the presence of TgAb-FNAB may contribute to the higher number of metastatic LNs with undetectable Tg-FNAB in the sTgAb+ group. In addition, the measurement of Tg-FNAB using different assays was useful to enhance the diagnosis of metastatic LNs, particularly when cytological and Tg-FNAB results are discordant.

Published
2017
Full Text
View/download PDF

3. Whole-brain white matter network reorganization in HIV

Author

F. Di Cio, S. Minosse, E. Picchi, F. Di Giuliano, L. Sarmati, E. Teti, M. Andreoni, R. Floris, M. Guerrisi, F. Garaci, and N. Toschi

Subjects
Parietal Lobe, Connectome, Brain, Humans, HIV Infections, White Matter
Abstract

The human immunodeficiency virus (HIV) causes an infectious disease with a high viral tropism toward CD4 T-lymphocytes and macrophage. Since the advent of combined antiretroviral therapy (CART), the number of opportunistic infectious disease has diminished, turning HIV into a chronic condition. Nevertheless, HIV-infected patients suffer from several life-long symptoms, including the HIV-associated neurocognitive disorder (HAND), whose biological substrates remain unclear. HAND includes a range of cognitive impairments which have a huge impact on daily patient life. The aim of this study was to examine putative structural brain network changes in HIV-infected patient to test whether diffusion-imaging-related biomarkers could be used to discover and characterize subtle neurological alterations in HIV infection. To this end, we employed multi-shell, multi-tissue constrained spherical deconvolution in conjunction with probabilistic tractography and graph-theoretical analyses. We found several statistically significant effects in both local (right postcentral gyrus, right precuneus, right inferior parietal lobule, right transverse temporal gyrus, right inferior temporal gyrus, right putamen and right pallidum) and global graph-theoretical measures (global clustering coefficient, global efficiency and transitivity). Our study highlights a global and local reorganization of the structural connectome which support the possible application of graph theory to detect subtle alteration of brain regions in HIV patients.Clinical Relevance-Brain measures able to detect subtle alteration in HIV patients could also be used in e.g. evaluating therapeutic responses, hence empowering clinical trials.

Published
2021

4. Phylogeography And Genomic Epidemiology of SARS-CoV-2 In Italy And Europe With Newly Characterized Italian Genomes

Author

Giovanni Tonon, Stefano Menzo, Emmanuele Venanzi Rullo, Marina Morganti, Sergio Babudieri, Guido Antonelli, Arianna Miola, Ilaria Vicenti, Gianguglielmo Zehender, Giuseppe Nunnari, Valeria Ghisetti, Daniela Francisci, Alessia Lai, Andrea Crisanti, M. Andreoni, Caterina Sagnelli, Daniela Maria Cirillo, L. Sarmati, Annapaola Callegaro, Ilaria Menozzi, Bianca Bruzzone, Annalisa Bergna, Massimo Galli, Davide Guarneri, Mauro Codeluppi, Francesco Cerutti, Andrea Orsi, Gaetano Brindicci, Stefano Toppo, Sara Caucci, Claudio Maria Mastroianni, Roberta Schiavo, Laura Monno, Vito Fiore, and Coppola N

Subjects
Phylogeography, medicine.medical_specialty, Evolutionary biology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Epidemiology, medicine, Biology, Genome
Abstract

The aims of this study were to characterize new SARS-CoV-2 genomes sampled all over Italy and to reconstruct the origin and the evolutionary dynamics in Italy and Europe between February and June 2020. The cluster analysis showed only small clusters including

Published
2021

5. Evolutionary Dynamics of SARS-CoV-2 in Space and Time During the First Phase of the Epidemic in Italy

Author

Daniela Maria Cirillo, Emmanuele Venanzi Rullo, Giovanni Tonon, Stefano Menzo, Marina Morganti, Andrea Orsi, Valeria Ghisetti, Roberta Schiavo, M. Andreoni, Davide Guarneri, Mauro Codeluppi, Laura Monno, Francesco Cerutti, Vito Fiore, Bianca Bruzzone, Annalisa Bergna, Gaetano Brindicci, Claudio Maria Mastroianni, Coppola N, L. Sarmati, Annapaola Callegaro, Daniela Francisci, Sara Caucci, Andrea Crisanti, Ilaria Menozzi, Stefano Toppo, Caterina Sagnelli, Giuseppe Nunnari, Sergio Babudieri, Guido Antonelli, Ilaria Vicenti, Alessia Lai, Massimo Galli, Gianguglielmo Zehender, and Arianna Miola

Subjects
Physics, Spacetime, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Phase (waves), biochemistry, Statistical physics, Evolutionary dynamics
Abstract

The aim of this study was the reconstruction of SARS-CoV-2 evolutionary dynamics in time and space in Italy and Europe between February and June 2020. The cluster analysis showed that pure Italian clusters were observed mainly after the lockdown and distancing measures were adopted. Lineage B and B.1 spread between late January and early February 2020, from China to Veneto and Lombardy, respectively. Lineage B.1.1 most probably evolved within Italy and spread from central to south Italian regions, and to European countries. The lineage B.1.1.1 entered Italy only in the second half of March and remained localized in Piedmont until June 2020. In conclusion, the reconstructed ancestral scenario suggests a central role of China and Italy in the widespread diffusion of the D614G variant in Europe in the early phase of the pandemic and more dispersed exchanges involving several European countries from the second half of March 2020.

Published
2021

6. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL

Author

Bruno Cacopardo, M. A. Ursitti, Claudio Maria Mastroianni, Emanuele Nicastri, R. Piolini, A. Antinori, Giustino Parruti, S. Truffa, Ivan Gentile, Giovanni Cassola, E. Girardi, I. Caramma, Andrea Calcagno, Laura Monno, A d'Arminio Monforte, R. Acinapura, Francesca Ceccherini-Silberstein, A. Di Biagio, Gabriella Verucchi, Alessandra Latini, Simone Marcotullio, Nicola Gianotti, C. Balotta, Camilla Tincati, M. C. Moioli, Alessandro Tavelli, Pietro Caramello, Carmen Rita Santoro, C. Abeli, A. Londero, F. Di Martino, R. Iardino, Stefano Bonora, M. Andreoni, A. Costantini, Raffaella Libertone, F. von Schloesser, G. Prota, Annalisa Saracino, Maria Grazia Cecchetto, Antonio Cristaudo, Mauro Zaccarelli, Carmela Pinnetti, Fabrizio Carletti, N. Abrescia, Andrea Giacometti, L. Gallo, Paolo Bonfanti, G. Angarano, E. Quiros Roldan, G. Pellizzer, F. Petrone, Giovanni Mazzarello, Silvia Nozza, R. Orlando, Franco Baldelli, Giovanni Guaraldi, Paola Meraviglia, Laura Sighinolfi, S. Carrara, D. Segala, Giuliano Rizzardini, C. Suardi, P. Piano, Mauro Sciandra, Daniela Francisci, A. De Luca, Patrizia Lorenzini, Paola Cinque, Tiziana Quirino, S. Graziano, Cristina Mussini, Massimo Galli, Giuseppe Ippolito, S. Lo Caputo, Benedetto Maurizio Celesia, C. Valeriani, Matteo Bassetti, Maria Rosaria Capobianchi, Claudio Viscoli, Vinicio Manfrin, Alessandro Chiodera, Alessandra Bandera, Guglielmo Borgia, Cinzia Puzzolante, Stefano Rusconi, Leonardo Calza, Valeria Belvisi, Francesca Vichi, Serena Quartu, Roberto Cauda, J. Vecchiet, Antonio Chirianni, A. Di Caro, P.E. Manconi, Stefania Cicalini, G. Magnani, M. Lichtner, Milensu Shanyinde, Stefano Savinelli, M. Puoti, Giulia Marchetti, Laura Carenzi, Carlo Federico Perno, Annalisa Ridolfo, G. Di Perri, F. Maggiolo, A Castagna, G. Orofino, Roberto Rossotti, Francesco Mazzotta, Gianmaria Baldin, Giovanni Lapadula, A. Rodano, V. Donati, Barbara Rossetti, F. Viviani, Adriana Ammassari, N. Bobbio, Adriano Lazzarin, C. Minardi, A. Alessandrini, Katia Falasca, Maria Stella Mura, Tamara Ursini, Andrea Gori, A. Cingolani, L. Maddaloni, Alessandro Cozzi-Lepri, Francesco Castelli, Iuri Fanti, Giordano Madeddu, E. Quiros, P. Viale, Marco Borderi, M. Capozzi, and Vincenzo Vullo

Subjects
Adult, Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Anti-HIV Agents, Hepatitis C virus, Renal function, Integrase inhibitor, HIV Infections, medicine.disease_cause, Rate ratio, 03 medical and health sciences, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Internal medicine, Clinical endpoint, Humans, Medicine, Pharmacology (medical), Treatment Failure, 030212 general & internal medicine, Retrospective Studies, Pharmacology, AIDS-Related Opportunistic Infections, Coinfection, business.industry, Retrospective cohort study, Middle Aged, Viral Load, 030112 virology, CD4 Lymphocyte Count, Discontinuation, Treatment Outcome, Infectious Diseases, Cohort, Female, business
Abstract

ObjectivesOur aim was to investigate the durability of different initial regimens in patients starting ART with CD4+ counts 5 log10 copies/mL.MethodsThis was a retrospective study of HIV-infected patients prospectively followed in the ICONA cohort. Those who started ART with boosted protease inhibitors (bPIs), NNRTIs or integrase strand transfer inhibitors (InSTIs), with CD4+ 5 log10 copies/mL, were included. The primary endpoint was treatment failure (TF), a composite endpoint defined as virological failure (VF, first of two consecutive HIV-RNA >50 copies/mL after 6 months of treatment), discontinuation of class of the anchor drug or death. Independent associations were investigated by Poisson regression analysis in a model including age, gender, mode of HIV transmission, CDC stage, HCV and HBV co-infection, pre-treatment HIV-RNA, CD4+ count and CD4+/CD8+ ratio, ongoing opportunistic disease, fibrosis FIB-4 index, estimated glomerular filtration rate, haemoglobin, platelets, neutrophils, calendar year of ART initiation, anchor drug class (treatment group) and nucleos(t)ide backbone.ResultsA total of 1195 patients fulfilled the inclusion criteria: 696 started ART with a bPI, 315 with an InSTI and 184 with an NNRTI. During 2759 person-years of follow up, 642 patients experienced TF. Starting ART with bPIs [adjusted incidence rate ratio (aIRR) (95% CI) 1.62 (1.29–2.03) versus starting with NNRTIs; P ConclusionsIn patients starting ART with 5 log10 HIV-RNA copies/mL, the durability of regimens based on InSTIs was longer than that of NNRTI- and bPI-based regimens.

Published
2019

7. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease

Author

L, Scucchi, B, Neri, L, Sarmati, M, Mossa, G, Sena, R, Massoud, C, Petruzziello, M, Musumeci, I, Marafini, E, Calabrese, E, Lolli, S, Bernardini, M, Andreoni, G, Monteleone, and L, Biancone

Subjects
Adult, Male, SARS-CoV-2, COVID-19, Middle Aged, Inflammatory Bowel Diseases, Cohort Studies, Crohn Disease, Risk Factors, Seroepidemiologic Studies, Prevalence, Humans, Colitis, Ulcerative, Female, Prospective Studies, Aged
Abstract

Treatments used in Inflammatory Bowel Disease (IBD) have been associated with enhanced risk of viral infections and viral reactivation, however, it remains unclear whether IBD patients have increased risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The aim of the study was to examine the prevalence of SARS-CoV-2 IgG positivity in IBD patients followed at our referral center. The role of treatments for IBD and risk factors for infection were also evaluated.In a prospective study, all IBD patients followed at our referral centre between May 27th and July 21st, 2020 and fulfilling the inclusion criteria were tested for SARS-CoV-2 IgG. Specific IgG antibodies were evaluated by a commercial ELISA kit and SARS-CoV-2 nasopharyngeal swab was performed in seropositive patients.Two-hundred and eighteen patients, 128 Crohn's disease (CD) and 90 Ulcerative colitis (UC) [age 44, (19-77) years; ongoing biologics in 115 (52.7%)] were enrolled. No patient had major SARS-CoV-2-related symptoms. SARS-CoV-2 IgG were detected in 3 out of 218 (1.37%) patients with IBD (2 CD and 1 UC), all on biologics (2.6%). In all of the 3 seropositive patients, the nasopharyngeal swab was negative. There was no relationship between SARS-CoV-2 seroprevalence and the demographic/clinical characteristics of IBD patients. In contrast, history of recent travel was more frequent in the SARS-CoV-2 seropositive patients (2/3; 66.6%) than in SARS-CoV-2 seronegative patients [7/215 (3.25%); p0.0001].The prevalence of SARS-CoV-2 IgG seropositivity in IBD patients appears to be comparable to the non-IBD population and not influenced by ongoing treatments. Risk factors for infection common to the general non-IBD population should be considered when managing patients with IBD.

Published
2021

8. HIV MDR is still a relevant issue despite its dramatic drop over the years

Author

Vanni Borghi, A. Antinori, Daniele Armenia, Raffaella Marocco, Cristina Mussini, Lavinia Fabeni, M. Andreoni, M Licthner, Francesca Ceccherini-Silberstein, Carmela Pinnetti, C.F. Perno, Philippe Flandre, Aldo Bertoli, Annalisa Mondi, Vincenzo Malagnino, Domenico Di Carlo, M. Santoro, Manuela Colafigli, Stefania Cicalini, Federica Forbici, William Gennari, Alessandra Latini, Francesco Montella, Yagai Bouba, Roberta Gagliardini, Rita Bellagamba, Caterina Gori, and Alessandra Vergori

Subjects
Microbiology (medical), medicine.medical_specialty, Genotype, Anti-HIV Agents, Human immunodeficiency virus (HIV), Integrase inhibitor, HIV Infections, Drug resistance, medicine.disease_cause, Settore MED/07, Internal medicine, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Medicine, Humans, Pharmacology (medical), Treatment Failure, Pharmacology, business.industry, Proportional hazards model, Regimen, Infectious Diseases, Drug class, Italy, HIV-1, business
Abstract

ObjectivesTo evaluate the prevalence and therapeutic relevance of drug resistance among isolates from ART-experienced HIV-1-infected patients over the past two decades in Italy.MethodsDynamics of resistance to one, two and three or more antiretroviral classes were evaluated from 1999–2018. Virological success (VS) after the latest therapy switch was evaluated according to cumulative class resistance and cumulative genotypic susceptibility score (Stanford HIV_DB algorithm).ResultsAmong 13 663 isolates (from 6739 patients), resistance to at least one drug class decreased sharply from 1999 to 2010 (≤2001, 84.6%; 2010, 43.6%; P ConclusionsA dramatic drop of HIV-1 drug resistance at failure has been achieved over the last two decades in Italy; resistance to three or more classes is low but present among currently failing patients. Its management still requires a rational and careful diagnostic and therapeutic approach.

Published
2020

9. 95 A rare case of Lactobacillus Plantarum prosthetic valve endocarditis

Author

R Mollace, M Stelitano, G Uccello, P Sordillo, Cammalleri, A Tavernese, M Andreoni, A Mauceri, S Muscoli, F Caldara, and Francesco Romeo

Subjects
medicine.medical_specialty, Lactobacillus casei, biology, business.industry, General Medicine, biology.organism_classification, medicine.disease, Surgery, Lactobacillus rhamnosus, Lactobacillus, Bacteremia, medicine, Endocarditis, Radiology, Nuclear Medicine and imaging, Gentamicin, Cardiology and Cardiovascular Medicine, Prosthetic valve endocarditis, business, Lactobacillus plantarum, medicine.drug
Abstract

INTRODUCTION Lactobacillus species are rare human pathogens but have been implicated in a variety of infections, including bacteremia and endocarditis, with Lactobacillus casei and Lactobacillus rhamnosus among the most frequently isolated species. Endocarditis due to Lactobacillus represents CASE REPORT Our patient is a 48 year-old male with a past medical history of surgical aortic replacement with a biological prosthetic valve in 2013. He reports the onset of symptoms 4 months before with worsening asthenia. The patient presented to a cardiologist after 3 months from symptoms beginning. A transesophageal echocardiogram (TEE) described marked fibro-plastic thickening of the cusps with two elongated vegetations (12 mm and 7 mm) causing a moderate-to-severe aortic steno-regurgitation. A few days later he came to our emergency department. On admission, the patient was afebrile, eupnoeic on room air. The cardiac examination revealed a regular rate and rhythm with a grade 4 of 6 holosystolic murmur loudest at the aortic and pulmonary focus. Three sets of blood cultures were drawn on admission. Hence, he was transferred to the Infectious Diseases Department where he started antibiotic therapy with Ceftriaxone and Gentamicin. A 18F-FDG PET-CT total body showed tracer accumulation close to the prosthetic aortic valve. Few days later Lactobacillus Plantarum was isolated from blood cultures and, according to the antibiogram results, therapy was adjusted using G Penicillin, Vancomicyn and Gentamicin. The TEE, performed during the hospitalization, showed one mobile vegetation, reduced in size (5 mm), adherent to the anterior aortic cusp, which prolapsed in the left ventricular outflow tract and commissural fusion, causing severe steno-regurgitation (Gmax 84 mmHg, Gmed 54 mmHg). During hospitalization the serial blood cultures resulted negative. Serial TEEs were also performed (3rdand 6thweek), showing a gradual reduction of the cusps thickening and disappearance of commissural fusion (Figure). In the last TEE no vegetations were described, and the transaortic mean gradient was reduced (Gmed 38 mmHg), persisting severe regurgitation. Hence the patient was discharged with oral antibiotic therapy (amoxicillin and clavulanic acid) and indication to redo aortic valve surgery. Written informed consent was obtained. CONCLUSIONS L. plantarum is a rare form of endocarditis. In our patient it caused fibro-plastic thickening of the bioprosthesis cusps and commissural fusion, determining severe steno-regurgitation. It also responded to targeted antibiotic therapy with improvement in cusp mobility but persistence of severe regurgitation. Abstract 95 Figure

Published
2020

10. The Combined use of Calcitonin Doubling time and 18F-FDG PET/CT Improves Prognostic Values in Medullary Thyroid Carcinoma: the Clinical Utility of 18F-FDG PET/CT

Author

Cleber P. Camacho, Lilian Yuri Itaya Yamaga, Ji H. Yang, Jairo Wagner, Flávia O. F. Valente, Susan C. Lindsey, Rui M. B. Maciel, Danielle M. Andreoni, and Rosa Paula M. Biscolla

Subjects
medicine.medical_specialty, medicine.diagnostic_test, biology, business.industry, Endocrinology, Diabetes and Metabolism, Medullary thyroid cancer, 030209 endocrinology & metabolism, Standardized uptake value, medicine.disease, Thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Carcinoembryonic antigen, Positron emission tomography, Calcitonin, 030220 oncology & carcinogenesis, medicine, biology.protein, Doubling time, Radiology, business, Nuclear medicine, Progressive disease
Abstract

Objective: Calcitonin and carcinoembryonic antigen (CEA) doubling times are established prognostic markers in medullary thyroid cancer (MTC). On the other hand, 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) shows an increased rate of detection with high blood tumor marker levels in several cancers. This study aimed to analyze the ability of 18F-FDG PET/CT to determine prognosis in the follow-up of patients with MTC. Methods: Medical records of 17 patients with MTC who underwent 18F-FDG PET/CT were analyzed retrospectively. All patients were classified into two groups: stable disease or progressive disease. Results: Eight patients presented with progressive disease, and all of them showed 18F-FDG uptake (100%), compared to only 3 of 9 patients who presented in stable condition (33%). 18F-FDG PET/CT results were able to distinguish progressive from stable disease (P = .009). Calcitonin levels >4,020 pg/mL (P = .0004), CEA levels >26.8 ng/mL (P = .04), and a calcitonin doubling time Conclusion:18F-FDG uptake was able to distinguish progressive from stable disease. However, this tool should not replace the validated calcitonin doubling time, but rather the combination of information could improve the clinical re-assessment and better identify high-risk patients who require more careful surveillance. Abbreviations: CEA = carcinoembryonic antigen CT = computed tomography 18F-FDG = 18F-fluorodeoxyglucose MTC = medullary thyroid cancer PET = positron emission tomography PVE = proportion of variance explained sCT = serum calcitonin SUV = standard uptake value US = ultrasound

Published
2017

11. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

Author

Anna Claudia Pellicelli, Alessandro Pieri, Enzo Boeri, V. Pace Palitti, Roberto Gulminetti, V. Di Marco, Stefania Paolucci, Simona Landonio, F. Di Lorenzo, Laura Monno, L. Sarmati, Stefano Novati, Annapaola Callegaro, Simona Marenco, G. Raimondo, Lavinia Fabeni, Maurizio Zazzi, Silvia Barbaliscia, Nicola Coppola, P. Andreone, L. Carioti, Claudio Maria Mastroianni, Anna Licata, Fausto Baldanti, M. Andreoni, M. Quartini, M. Lichtner, Gloria Taliani, Laura Ambra Nicolini, Francesca Ceccherini-Silberstein, C.F. Perno, Luca Foroghi, Giustino Parruti, Bianca Bruzzone, Caterina Pasquazzi, C. Paternoster, Martina Milana, Sergio Babudieri, K. Yu La Rosa, M. Puoti, Hamid Hasson, Teresa Pollicino, N. Iapadre, C. Minichini, Raffaele Cozzolongo, Valeria Micheli, Barbara Rossetti, Aldo Bertoli, Elisabetta Teti, Marianna Aragri, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Vincenzo Sangiovanni, Leonardo Baiocchi, and Mario Angelico

Subjects
Genetics, Hepatology, Resistance (ecology), Phylogenetic tree, business.industry, Gastroenterology, Medicine, business
Published
2020

12. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

Author

C.F. Perno, A. Iuvara, Carlotta Cerva, Sandro Grelli, Mario Angelico, Carla Fontana, V. Svicher, Mohammad Alkhatib, R. Salpini, Aldo Bertoli, L. Sarmati, Mario Starace, M. De Cristofaro, F. Ceccherini Silberstein, Nicola Coppola, L. Piermatteo, Giuseppina Cappiello, Mariantonietta Pisaturo, Carmine Minichini, and M. Andreoni

Subjects
Hepatology, HBeAg, business.industry, medicine.medical_treatment, Immunology, Treatment outcome, Gastroenterology, medicine, Hbv reactivation, Immunosuppression, business
Published
2020

13. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Mario Starace, Valerio Giannelli, Nunzia Cuomo, Vanni Borghi, Aldo Bertoli, Anna Licata, Anna Claudia Pellicelli, C. Minichini, M. Andreoni, M. Di Stefano, Giuseppe Cariti, Enzo Boeri, Raffaele Cozzolongo, Roberto Gulminetti, E. Milano, Valeria Cento, Elisabetta Degasperi, Laura Sighinolfi, A. Raddi, Ivana Maida, Barbara Rossetti, Teresa Santantonio, Valeria Micheli, C. Masetti, P. Andreone, Giustino Parruti, F. Di Lorenzo, Ilaria Lenci, Tiziano Allice, Annapaola Callegaro, Elisa Biliotti, M. Lichtner, Teresa Pollicino, Pietro Lampertico, Gloria Taliani, Caterina Pasquazzi, Piero Colombatto, Alessia Giorgini, G. Raimondo, Antonio Craxì, Francesca Ceccherini-Silberstein, Filomena Morisco, Valeria Ghisetti, V.C. Di Maio, Giuliano Rizzardini, Silvia Galli, Stefania Paolucci, A. De Santis, A. Lleo, Vincenzo Sangiovanni, A. Ciancio, Maurizio Zazzi, Elisabetta Teti, Simona Marenco, William Gennari, Stefano Novati, Giovanni Cenderello, Simona Landonio, Manuela Merli, A. Scuteri, Nicola Coppola, C.F. Perno, Giulia Morsica, I. Beretta, Claudio Maria Mastroianni, Simona Francioso, Mario Angelico, Laura Ambra Nicolini, Chiara Dentone, Silvia Barbaliscia, G.B. Gaeta, Marianna Aragri, Ennio Polilli, L. Donnarumma, Vincenza Calvaruso, Bianca Bruzzone, Fausto Baldanti, V. Pace Palitti, Roberto Ganga, Maurizia Rossana Brunetto, C. Paternoster, Sergio Babudieri, M. Puoti, Hamid Hasson, and M. Rendina

Subjects
medicine.medical_specialty, Regimen, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business, NS5A
Published
2020

14. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection

Author

Angelico Mario, U.S. Gill, Luna Colagrossi, L. Sarmati, Claudio Maria Mastroianni, Marianna Aragri, F. Ceccherini Silberstein, Massimo Marignani, Carlotta Cerva, J. Vecchiet, N. Iapadre, Giustino Parruti, Vincenzo Malagnino, T. Mari, M. Lichtner, R. Salpini, A. Battisti, Olympia E. Anastasiou, M. Andreoni, G. De Sanctis, L. Piermatteo, Sandro Grelli, A. Iuvara, Aldo Bertoli, L. Carioti, V. Svicher, Jens Verheyen, Caterina Pasquazzi, Patrick T F Kennedy, P. Maurizio, and C.F. Perno

Subjects
HBsAg, Hepatology, business.industry, C-terminus, Gastroenterology, Medizin, Affect (psychology), Virology, In vitro, Hbeag negative, In vivo, Hbv genotype, Medicine, business
Published
2019

15. PIN38 Cost-Effectiveness of Expanded HIV Screening Among Adult Population in Italy

Author

Andrea Marcellusi, Loredana Sarmati, M. Andreoni, F.S. Mennini, M. Paoletti, M. Rotundo, A. Antinori, and C. Bini

Subjects
business.industry, Cost effectiveness, Health Policy, Environmental health, Public Health, Environmental and Occupational Health, Adult population, Medicine, HIV screening, business
Published
2020

16. Hydrodissection and programmed stop sedation in 100 % of benign thyroid nodules treated with radiofrequency ablation

Author

Marcos Roberto Gomes de Queiroz, Priscila Mina Falsarella, Erivelto Martinho Volpi, Miguel Jose Francisco-Neto, Danielle M. Andreoni, Katia Pinheiro de Souza, Jairo Tabacow Hidal, Antonio Rahal, and Rodrigo Gobbo Garcia

Subjects
Thyroid nodules, medicine.medical_specialty, Percutaneous, Under sedation, Radiofrequency ablation, Sedation, medicine.medical_treatment, 030218 nuclear medicine & medical imaging, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, medicine, Humans, Radiology, Nuclear Medicine and imaging, Thyroid Nodule, Retrospective Studies, Ultrasonography, Radiofrequency Ablation, business.industry, Thyroid, Retrospective cohort study, General Medicine, Ablation, medicine.disease, Surgery, Treatment Outcome, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Catheter Ablation, medicine.symptom, business
Abstract

Purpose To describe our group experience in treatment of benign symptomatic thyroid nodules using radiofrequency ablation technique always associated to routine pre-procedure hydrodissection and under sedation with programmed stop. Methods Dual-center, retrospective study conducted between April 2018 and January 2020. A total of 52 symptomatic benign thyroid nodules were treated in 34 patients with ultrasound-guided percutaneous radiofrequency ablation. The technique of choice was moving-shot technique and 100 % patients underwent pre-procedural hydrodissection with 5% glucose solution, plus conscious sedation with programmed stop during procedure. Results Most nodules were solid or almost completely solid (n = 45, 88.3 % of nodules), followed by cystic composition (n = 4, 7.8 %) and mixed (n = 2, 3.9 %). As for location, most were on the right lobe (n = 29, 56.9 %), followed by the left lobe (n = 17, 33.3 %) and isthmus (n = 5, 9.8 %). The average volume of nodules before ablation was 18.2 ± 20.5 mL. Volumetric reduction rates at one, three, six and twelve months after ablation were 46.6 %, 64.5 %, 76.1 % and 88.8 %, respectively. No complications strictly related to procedure were reported. No more than 5 min were added to total time of ablative treatment considering routine hydrodissection and stop programmed sedation. Conclusions Minimally invasive therapies applied to thyroid allow the preservation of healthy thyroid parenchyma and provide a very effective volumetric reduction of symptomatic benign thyroid nodules. Hydrodissection with 5 % glucose solution, conscious sedation and patient stimulation with programmed stop during procedure may provide greater safety to procedure, and, in our experience, could be done routinely in all patients.

Published
2020

17. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens

Author

Claudia Alteri, Daniele Armenia, Ada Bertoli, M. Andreoni, Gaetano Maffongelli, Andrea Antinori, Cristina Mussini, Vanni Borghi, Emanuele Nicastri, Federica Forbici, Domenico Di Carlo, Caterina Gori, Francesca Ceccherini-Silberstein, Mauro Zaccarelli, Mm Santoro, Massimo Giuliani, Gianpiero D'Offizi, Carmela Pinnetti, Stefania Cicalini, and Carlo Federico Perno

Subjects
Adult, Male, 0301 basic medicine, medicine.medical_specialty, Adolescent, Anti-HIV Agents, 030106 microbiology, virological response, HIV Infections, darunavir, Drug resistance, Gastroenterology, Virological response, Young Adult, 03 medical and health sciences, darunavir dosage, Interquartile range, Internal medicine, Drug Resistance, Viral, medicine, Humans, Pharmacology (medical), Treatment Failure, Viral, Young adult, Darunavir, Ritonavir, drug resistance, business.industry, Health Policy, Middle Aged, Viral Load, Settore MED/07 - Microbiologia e Microbiologia Clinica, Surgery, baseline viraemia, Female, HIV-1, Regimen, Infectious Diseases, business, Viral load, medicine.drug
Abstract

Objectives We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. Methods Data from 206 drug-naive and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses. Baseline DRV/r resistance and its evolution at failure were also examined. Results DRV600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD4 cell count and DRV/PI resistance) compared with DRV800. By 12 months, the probability of achieving VS was 93.2% and 84.3% in drug-naive and PI-experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS, both in drug-naive patients [>500 000 HIV-1 RNA copies/mL: median [interquartile range (IQR)] 6.1 (5.1–10.3) months; 100 000–500 000 copies/mL: median (IQR) 4.9 (3.8–6.1) months

Published
2016

18. PS-1-8 Attitudes and Knowledge Towards Homosexuality: An Observational Study on a Sample of Medical Students

Author

M. Andreoni, L. Toccini, E.A. Jannini, Giacomo Ciocca, Elena Colonnello, Erika Limoncin, and G. Moscato

Subjects
Psychiatry and Mental health, Endocrinology, Reproductive Medicine, Urology, Endocrinology, Diabetes and Metabolism, media_common.quotation_subject, Observational study, Sample (statistics), Homosexuality, Psychology, media_common, Clinical psychology
Published
2020

19. The combined usage of accurate virological and serological HBV markers can help to identify HBsAg-negative/anti-HBc-positive patients at higher risk of HBV-reactivation and to optimize prophylaxis duration in oncohematological setting

Author

C.F. Perno, M.L. Cantonetti, A. Battisti, M. Andreoni, Vincenzo Malagnino, V. Svicher, Mohammad Alkhatib, Lavinia Fabeni, R. Salpini, F. Ceccherini-Silberstein, L. Sarmati, Carlotta Cerva, L. Piermatteo, and William Arcese

Subjects
Anti hbc, Hbsag negative, Hepatology, business.industry, Immunology, Gastroenterology, Hbv reactivation, Hbv markers, Medicine, business, Serology
Published
2020

20. PMU29 ECONOMIC EVALUATION FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURES INFECTIONS (ABSSSI) FROM THE NATIONAL PAYER PERSPECTIVE: INTRODUCTION OF A NEW TREATMENT INTO THE PATIENT JOURNEY. SIMULATION IN 3 EUROPEAN COUNTRIES

Author

P. Horcajada Gallego, Giampiero Favato, C. Bini, Loredana Sarmati, T. Czypionka, Jaime Espín, F.S. Mennini, M. Andreoni, and Andrea Marcellusi

Subjects
Economic growth, Health Policy, Political science, Perspective (graphical), Economic evaluation, Public Health, Environmental and Occupational Health
Published
2019

21. Bethesda Classification and Cytohistological Correlation of Thyroid Nodules in a Brazilian Thyroid Disease Center

Author

Rosalia P. Padovani, Elsa S Ikejiri, Felipe Augusto Brasileiro Vanderlei, Rui M. B. Maciel, Ji H. Yang, Maria Conceição Mamone, Kassia B Reuters, Cláudia C. D. Nakabashi, Danielle M. Andreoni, Rosa Paula M. Biscolla, Carolina Castro Porto Silva Janovsky, and Cleber P. Camacho

Subjects
Thyroid nodules, medicine.medical_specialty, Suspicious for Malignancy, Clinical Thyroidology / Original Paper, medicine.diagnostic_test, business.industry, Endocrinology, Diabetes and Metabolism, Thyroid disease, Thyroid, Bethesda system, 030209 endocrinology & metabolism, medicine.disease, Malignancy, 03 medical and health sciences, 0302 clinical medicine, Fine-needle aspiration, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Atypia, Medicine, Radiology, business
Abstract

Background The Bethesda System has been used to classify thyroid cytology in 6 categories besides presenting malignancy rates and respective approaches. Reference centers have validated its use by comparing its proposed malignancy rates with those in in their populations. However, to the best of our knowledge, there has been no corresponding study in Brazil. Objectives To evaluate the performance of the Bethesda classification in a Brazilian thyroid reference center and correlate the results with cytohistological reports in patients referred to surgery. Methods Data records from 980 fine-needle aspiration (FNA) results were retrospectively analyzed, and, in patients who underwent surgery, the results were correlated with the cytohistological findings. Results 980 FNAs and 585 patients were evaluated. The incidence of each cytological category was: 11% nondiagnostic (ND), 59.6% benign, 7.1% (atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS), 8.5% follicular neoplasm or suspicious for follicular neoplasm (FN/SFN), 5.1% suspicious for malignancy (SM), and 8.3% malignant. The surgery rate was 41.8% (245/585). The malignancy rate in each category was: 6% benign, 12% AUS/FLUS, 20.8% FN/SFN, 72.5% SM, and 97.3% malignant. For ND nodules, the malignancy rate was 25.7% (66.6% multifocal and papillary microcarcinomas), a higher rate than in the literature. In this category, surgery was performed in multinodular goiters presenting with another nodule > 3.0 cm and/or with an FN/SFN, SM, or malignant cytological result. Conclusion The Bethesda System can be applied to the Brazilian population, since the frequency and malignancy rates of each category were similar to those described by its classification. It is noteworthy that a higher risk of malignancy was observed in the ND cytological category.

Published
2018

22. A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

Author

Angelico Mario, L. Sarmati, L. Piermatteo, Sarah Maylin, C.F. Perno, A. Battisti, M. Andreoni, Laura Belloni, Constance Delaugerre, N. Iapadre, Claudio Maria Mastroianni, Massimo Levrero, Massimo Marignani, Marianna Aragri, Luna Colagrossi, Francesca Ceccherini Silberstein, Jens Verheyen, R. Salpini, Aldo Marrone, Filomena Morisco, Aldo Bertoli, V. Svicher, Lavinia Fabeni, and Coppola Nicola

Subjects
chemistry.chemical_compound, HBsAg, Glycosylation, Hepatology, chemistry, Antigen, medicine.medical_treatment, Hbv reactivation, medicine, Medizin, Immunosuppression, Virology, In vitro
Published
2018

23. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

Author

M. Siciliano, Giulia Morsica, Anna Claudia Pellicelli, Silvia Galli, F. Ceccherini-Silberstein, Fausto Baldanti, Bianca Bruzzone, R. Campoli, Giuliano Rizzardini, Vincenza Calvaruso, Gloria Taliani, V. Pace Palitti, C. Masetti, P Paba, Antonio Craxì, Filomena Morisco, Ennio Polilli, V.C. Di Maio, Martina Milana, William Gennari, C.F. Perno, Rossana Scutari, Aldo Bertoli, Valeria Cento, M. Andreoni, V. Boccaccio, Marianna Aragri, G.B. Gaeta, M. Lichtner, Caterina Pasquazzi, Vanni Borghi, Laura Ambra Nicolini, Renato Maserati, G. Fiorentino, Sergio Babudieri, Elisabetta Degasperi, Giustino Parruti, Mario Angelico, L. Foroghi, Valeria Ghisetti, Silvia Barbaliscia, Carlo Magni, Valeria Micheli, Elisabetta Teti, Nicola Coppola, Stefania Paolucci, L. Sarmati, R. D’Ambrosio, Pietro Lampertico, M. Puoti, N. Iapadre, Stefano Bonora, and V. Guarneri

Subjects
Natural resistance, Oncology, Focus (computing), medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Treatment outcome, Gastroenterology, medicine, Baseline (configuration management), DIRECT ACTING ANTIVIRALS, business
Published
2019

24. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Pietro Lampertico, Valeria Cento, Claudio Maria Mastroianni, M. Puoti, Giuliano Rizzardini, Maurizio Zazzi, M. Lichtner, Bianca Bruzzone, Ivana Maida, Elisabetta Degasperi, C.F. Perno, M. Rendina, Giustino Parruti, Vincenza Calvaruso, Gloria Taliani, F. Di Lorenzo, Ilaria Lenci, Anna Claudia Pellicelli, Caterina Pasquazzi, Stefania Paolucci, A. Raddi, Marianna Aragri, Ennio Polilli, Giulia Morsica, Mario Starace, M. Andreoni, M. Di Stefano, C. Minichini, L. Donnarumma, V. Guarneri, Simona Marenco, Simona Landonio, Raffaele Cozzolongo, V. Pace Palitti, N. Cuomo, P. Andreone, Nicola Coppola, Silvia Galli, Mario Angelico, C. Paternoster, Roberto Ganga, Vanni Borghi, Elisabetta Teti, Sergio Babudieri, Silvia Barbaliscia, Anna Licata, Giovanni Cenderello, Antonio Craxì, Filomena Morisco, Maurizia Rossana Brunetto, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Piero Colombatto, Valeria Micheli, Teresa Pollicino, Laura Ambra Nicolini, Alessia Giorgini, Valeria Ghisetti, S. Novati, Annapaola Callegaro, Aldo Bertoli, E. Milano, Roberto Gulminetti, A. De Santis, F. Ceccherini-Silberstein, Teresa Santantonio, C. Masetti, G. Raimondo, Di Maio, V.C., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., Barbaliscia, S., Pollicino, T., Minichini, C., Calvaruso, V., Rendina, M., Cento, V., Teti, E., Micheli, V., Ghisetti, V., Polilli, E., Palitti, V. Pace, Landonio, S., Lenci, I., Donnarumma, L., Nicolini, L.A., Bertoli, A., Starace, M., Pasquazzi, C., Callegaro, A.P., Morisco, F., Cenderello, G., Marenco, S., Gulminetti, R., Novati, S., Guarneri, V., Andreone, P., Galli, S., Ciancio, A., Sangiovanni, V., Cuomo, N., Raddi, A., Morsica, G., Borghi, V., Maida, I., Brunetto, M., Colombatto, P., Cozzolongo, R., De Santis, A., Lichtner, M., Babudieri, S., Taliani, G., Santantonio, T., Di Stefano, M., Paternoster, C., Ganga, R., Puoti, M., Rizzardini, G., Pellicelli, A., Milano, E., Mastroianni, C., Licata, A., Di Lorenzo, F., Giorgini, A., Lampertico, P., Parruti, G., Coppola, N., Zazzi, M., Raimondo, G., Andreoni, M., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Subjects
Resistance test, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, DAA failur, Vironet C, NS5A, Regimen, Internal medicine, medicine, retreatment, business
Abstract

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/131/20), grazoprevir/elbasvir ± ribavirin (N = 34), glecaprevir/pibrentasvir (N = 20). Notably, 18.1% of NS5A-failing patients did not show any resistance-associated-substitutions (RAS), while 81.9% showed at least one NS5A-RAS, with multiclass-resistance in 35.5%. NS5A-RAS were observed more frequently in glecaprevir/pibrentasvir failures (GT1a 83.3%: Y93H + Q30H/D or +H58D; GT3a: 83.3% Y93H + A30K/G or +L31I) compared to sofosbuvir/velpatasvir (GT1a 16.6%: Y93H + Q30H, p = 0.08; GT3a 20.0%: Y93H/N + A30K/T, p = 0.03). To date, 105 failures have started a retreatment: sofosbuvir/velpatasvir ± ribavirin (N = 30), sofosbuvir/velpatasvir/voxilaprevir ± ribavirin (N = 67), glecaprevir/pibrentasvir (N = 4), grazoprevir/elbasvir ± sofosbuvir + ribavirin (N = 3), 3D + sofosbuvir + ribavirin (N = 1). The majority of patients were cirrhotic (51.9%) and relapsers (87.5%). The prevalence of NS5A-RASs before retreatment was 80.9%, with multiclass-resistance 29.5%. Among patients completing post-retreatment follow-up, a sustained-viral-response at week 12 (SVR12) was observed in 26/33 (78.8%). SVR4 was documented in 49/56 (87.5%). SVR12 was 76.0% with sofosbuvir/velpatasvir ± ribavirin (N = 25). Differently, SVR12 was 100% with glecaprevir/pibrentasvir for 8/12/16 weeks (N = 3), grazoprevir/elbasvir ± sofosbuvir + ribavirin for 12/24 weeks (N = 3) or 3D + sofosbuvir + ribavirin for 24 weeks (N = 1), despite the presence of NS5A-RASs. Until now, 67 patients started sofosbuvir/velpatasvir/voxilaprevir ± ribavirin recommended-retreatment for 12 weeks. 54/67 (80.6%) showed at least one baseline NS5A-RAS, 23/67 (34.3%) multiple-NS5A-RASs, and 22/67 (32.8%) multiclass-resistance. Of 25 patients with available outcome, 96.0% had SVR4. Only 1 GT1b infected patient was non-responder, without RASs before retreatment. Conclusions: In this real-life setting, NS5A-RASs were frequently detected at failure, and multiclass-resistance was around 30%. Overall, SVR after resistance-test-guided retreatment was >95%, with the exception of the sofosbuvir/velpatasvir retreatment. Our results show how HCV resistance-test at failure may be useful to optimize retreatment strategies.

Published
2019

25. Poster Session 4: Acute Liver Failure and Artificial Liver Support; Diagnostics, Epidemiology, and Natural History

Author

Antonio Gasbarrini, Francesco Russo, Liliana Chemello, Teresa Santantonio, Luchino Chessa, Paolo Caraceni, M. Puoti, Al Zignego, M. Rizzetto, Marco Marzioni, A. Di Leo, Carlo Ferrari, P. Andreone, Stefano Rosato, Pierluigi Blanc, A. Kondili L A Loreta, Me Tosti, Maurizia Rossana Brunetto, L. E. Weimer, G. Raimondo, Michele Quaranta, Raffaele Bruno, Carmine Coppola, Alessandra Mallano, Loredana Falzano, Gabriella Verucchi, Alfredo Alberti, G. Taliani, E.M. Erne, M Massella, Maria Cristina Vinci, Erica Villa, Marcello Persico, Stefano Vella, Giovanna Fattovich, De Rose Agostino Maria, G.B. Gaeta, M. Andreoni, Guglielmo Borgia, and Antonio Craxì

Subjects
Prioritization, Pediatrics, medicine.medical_specialty, Life evaluation, Hepatology, CpG site, business.industry, Cohort, Medicine, business, Studio
Published
2015

26. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND

Author

Ji H, Yang, Cléber P, Camacho, Susan C, Lindsey, Flavia O F, Valente, Danielle M, Andreoni, Lilian Y, Yamaga, Jairo, Wagner, Rosa Paula M, Biscolla, and Rui M B, Maciel

Subjects
Adult, Calcitonin, Male, Middle Aged, Prognosis, Carcinoembryonic Antigen, Carcinoma, Neuroendocrine, Cohort Studies, Young Adult, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Biomarkers, Tumor, Disease Progression, Humans, Female, Thyroid Neoplasms, Radiopharmaceuticals, Child, Aged, Retrospective Studies
Abstract

Calcitonin and carcinoembryonic antigen (CEA) doubling times are established prognostic markers in medullary thyroid cancer (MTC). On the other hand,Medical records of 17 patients with MTC who underwentEight patients presented with progressive disease, and all of them showedCEA = carcinoembryonic antigen CT = computed tomography

Published
2017

27. Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma

Author

Elza S. Ikejiri, Felipe Crispim, Danielle M. Andreoni, M Cecília Martins-Costa, Cleber P. Camacho, M. Conceição O. Mamone, Rui M. B. Maciel, Rosa Paula M. Biscolla, Teresa S. Kasamatsu, and Cláudia C. D. Nakabashi

Subjects
medicine.medical_specialty, Pathology, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Biopsy, Fine-Needle, Fluoroimmunoassay, lcsh:Medicine, 030209 endocrinology & metabolism, thyroglobulin, Gastroenterology, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Thyroglobulin, Papillary thyroid cancer, Thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Reference Values, Internal medicine, Biopsy, medicine, Carcinoma, Humans, papillary thyroid cancer, Thyroid Neoplasms, Lymph node, Thyroid cancer, neck lymph nodes, Autoantibodies, Ultrasonography, lcsh:RC648-665, medicine.diagnostic_test, business.industry, lcsh:R, Reproducibility of Results, medicine.disease, Carcinoma, Papillary, medicine.anatomical_structure, Fine-needle aspiration, Fine needle aspiration biopsy, Thyroid Cancer, Papillary, anti-thyroglobulin antibody, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Lymph Nodes, business, Neck
Abstract

Objectives The presence of thyroglobulin (Tg) in needle washouts of fine needle aspiration biopsy (Tg-FNAB) in neck lymph nodes (LNs) suspected of metastasis has become a cornerstone in the follow-up of patients with papillary thyroid carcinoma (PTC). However, there are limited data regarding the measurement of anti-Tg antibodies in these washouts (TgAb-FNAB), and it is not clear whether these antibodies interfere with the assessment of Tg-FNAB or whether there are other factors that would more consistently justify the finding of low Tg-FNAB in metastatic LNs. Materials and methods We investigated 232 FNAB samples obtained from suspicious neck LNs of 144 PTC patients. These samples were divided according to the patient’s serum TgAb status: sTgAb- (n = 203 samples) and sTgAb+ (n = 29). The TgAb-FNAB levels were measured using two different assays. Tg-FNAB was also measured using two assays when low levels (< 10 ng/mL) were identified in the first assay of the metastatic LNs from the sTgAb+ samples. Results The TgAb-FNAB results were negative in both assays in all samples. Low levels of Tg-FNAB were identified in 11/16 of the metastatic LNs of the sTgAb+ patients and 16/63 of the sTgAb- patients (p < 0.05) using assay 1. The measurement of the Tg-FNAB levels using assay 2 indicated additional metastases in 5 LNs of the sTgAb+ patients. Conclusions Factors other than the presence of TgAb-FNAB may contribute to the higher number of metastatic LNs with undetectable Tg-FNAB in the sTgAb+ group. In addition, the measurement of Tg-FNAB using different assays was useful to enhance the diagnosis of metastatic LNs, particularly when cytological and Tg-FNAB results are discordant.

Published
2017

28. The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification

Author

Carlotta Cerva, Lavinia Fabeni, R. Salpini, J. Vecchiet, Giustino Parruti, M. Visca, A. Iuvara, A. Battisti, S. Romano, L. Sarmati, Caterina Pasquazzi, Luna Colagrossi, M. Andreoni, N. Iapadre, Miriam Lichtner, Cesare Sarrecchia, A. Moretti, Domenico Di Carlo, T. Mari, A. Ricciardi, M. Paoloni, Alberto Spanò, Claudio Maria Mastroianni, V. Svicher, Massimo Marignani, Giuseppina Cappiello, C.F. Perno, V. Fini, L. Piermatteo, G. De Sanctis, Sandro Grelli, Mario Angelico, and Aldo Bertoli

Subjects
0301 basic medicine, HBsAg, Hepatology, business.industry, 030106 microbiology, Viremia, non avaiable, medicine.disease, Virology, 03 medical and health sciences, 0302 clinical medicine, Hbv genotype, Vaccine escape, Medicine, 030212 general & internal medicine, business
Published
2017

29. Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA

Author

R. Salpini, Claudio Maria Mastroianni, A. Battisti, M. De Cristofaro, Hervé Fleury, Rossana Scutari, Nicola Coppola, N. Iapadre, Pascale Trimoulet, Giuseppina Cappiello, C. Menichini, M. Andreoni, G. De Sanctis, V. Svicher, E. Nebuloso, M. Lichtner, Ilaria Lenci, Mario Angelico, Maria Stanzione, Aldo Bertoli, C.F. Perno, T. Mari, L. Piermatteo, Luna Colagrossi, Caterina Pasquazzi, Alberto Spanò, L. Sarmati, Vincenzo Malagnino, A. Barlattani, G. Stornaiuolo, Massimo Marignani, and Alfonso Galeota Lanza

Subjects
Hepatology, Antigen, Immunology, HEPATITIS DELTA, RNA, Genetic variability, Biology, Virology, Degree (temperature)
Published
2017

30. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

Author

L. Lambiase, Anna Claudia Pellicelli, Gloria Taliani, Barbara Menzaghi, Stefania Paolucci, Giuliano Rizzardini, Valeria Cento, Cesare Sarrecchia, Marianna Aragri, Francesca Ceccherini-Silberstein, M. Melis, M. Andreoni, Stefano Novati, Carlo Magni, Silvia Barbaliscia, Ilaria Lenci, V.C. Di Maio, Martina Milana, Elisabetta Teti, Mario Angelico, Caterina Pasquazzi, Aldo Bertoli, M. Puoti, A. Pecchioli, Valeria Micheli, Margherita Macera, Sergio Babudieri, Dante Romagnoli, Valeria Ghisetti, Laura Ambra Nicolini, Elisa Biliotti, Y. Troshina, Carlo Federico Perno, Fausto Baldanti, Simona Marenco, Nicola Coppola, T. Ruggiero, Manuele Koci Siciliano, Stefano Bonora, Alessia Ciancio, Cento, V, Barbaliscia, S, Lenci, I, Ruggiero, T, Magni, C, Paolucci, S, Babudieri, S, Siciliano, M, Pasquazzi, C, Ciancio, A, Perno, C, Ceccherini-Silberstein, F, Micheli, V, Troshina, Y, Biliotti, E, Milana, M, Melis, M, Teti, E, Lambiase, L, Menzaghi, B, Nicolini, L, Marenco, S, Di Maio, V, Aragri, M, Pecchioli, A, Bertoli, A, Sarrecchia, C, Macera, M, Coppola, N, Puoti, M, Romagnoli, D, Pellicelli, A, Bonora, S, Novati, S, Baldanti, F, Ghisetti, V, Andreoni, M, Taliani, G, Rizzardini, G, Angelico, M, Barbaliscia, I, and Ceccherini Silberstein, F

Subjects
0301 basic medicine, Male, Cirrhosis, Genotyping Techniques, Sustained Virologic Response, Hepacivirus, Treatment failure, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, NS5A-inhibitors, Genotypic resistance testing, Treatment Failure, Chronic, HCV resistance, biology, Direct acting antivirals, HCV failure, Protease-inhibitors, Retreatment, Adult, Aged, Antiviral Agents, Female, Hepatitis C, Chronic, Humans, Microbial Sensitivity Tests, Middle Aged, Protease Inhibitors, Sequence Analysis, DNA, General Medicine, Settore MED/07 - Microbiologia e Microbiologia Clinica, Protease-inhibitor, Hepatitis C, humanities, Infectious Diseases, DIrect acting antivirals, HCVFailure, hcv-resistance, 030211 gastroenterology & hepatology, Sequence Analysis, Microbiology (medical), medicine.medical_specialty, 03 medical and health sciences, Internal medicine, medicine, In real life, Protease inhibitor (pharmacology), Cirrhosi, business.industry, Ribavirin, DNA, biology.organism_classification, medicine.disease, Surgery, Regimen, 030104 developmental biology, chemistry, NS5A-inhibitor, Direct acting antiviral, business
Abstract

Objectives First-generation protease-inhibitors (PIs) have suboptimal efficacy in GT-1 patients with advanced liver disease, and patients experiencing treatment failure may require urgent retreatment. Our objective was to analyse the real-life efficacy of interferon (IFN)-free retreatment after PI-failure, and the role of genotypic-resistance-testing (GRT) in guiding retreatment choice. Methods In this multi-centre observational study, patients retreated with IFN-free regimens after first-generation PI-failure (telaprevir-boceprevir-simeprevir) were included. Sustained-virological-response (SVR) was evaluated at week 12 of follow-up. GRT was performed by population-sequencing. Results After PI-failure, 121 patients (cirrhotic = 86.8%) were retreated following three different strategies: A) with ‘GRT-guided’ regimens (N = 18); B) with ‘AASLD/EASL recommended, not GRT-guided’ regimens (N = 72); C) with ‘not recommended, not GRT-guided’ regimens (N = 31). Overall SVR rate was 91%, but all 18 patients treated with ‘GRT-guided’ regimens reached SVR (100%), despite heterogeneity in treatment duration, use of PI and ribavirin, versus 68/72 patients (94.4%) receiving ‘AASLD/EASL recommended, not GRT-guided’ regimens. SVR was strongly reduced (77.4%) among the 31 patients who received a ‘not recommended, not GRT-guided regimen’ (p

Published
2017

31. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?

Author

Aldo Bertoli, J. Vecchiet, Jens Verheyen, M. Andreoni, L. Piermatteo, Caterina Pasquazzi, Giustino Parruti, C.F. Perno, M. Paoloni, T. Mari, Carlotta Cerva, V. Fini, Claudio Maria Mastroianni, Vincenzo Malagnino, A. Battisti, Olympia E. Anastasiou, V. Svicher, N. Iapadre, R. Salpini, Lavinia Fabeni, Patrick T F Kennedy, U.S. Gill, Miriam Lichtner, Massimo Marignani, Luna Colagrossi, A. Iuvara, G. De Sanctis, Sandro Grelli, Mario Angelico, and L. Sarmati

Subjects
HBsAg, Hepatology, Hbeag negative, business.industry, Immunology, Medizin, Hbv genotype, Medicine, Quantitative hbsag, business, Virology, Degree (temperature)
Published
2017

32. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

Author

Simona Francioso, A. Ciaccio, Teresa Pollicino, Bianca Bruzzone, G. Fiorentino, V. Boccaccio, Coppola Nicola, M. Puoti, Ivana Maida, Valeria Cento, Lucio Boglione, Francesca Ceccherini Silberstein, Valeria Micheli, Silvia Barbaliscia, Sergio Babudieri, Guido Gubertini, Giustino Parruti, Antonio Craxì, Vincenzo Vullo, Ennio Polilli, M. Andreoni, Filomena Morisco, Vincenzo Sangiovanni, Vincenza Calvaruso, Renato Maserati, Velia Chiara Di Maio, Maurizio Zazzi, Marianna Aragri, A. Ciancio, Barbara Rossetti, Anna Claudia Pellicelli, Elisabetta Teti, C.F. Perno, Caterina Pasquazzi, L. Sarmati, R. D’Ambrosio, Mario Angelico, Fosca Niero, Stefano Bonora, M. Rendina, Gloria Taliani, Luca Foroghi, Laura Ambra Nicolini, Aldo Bertoli, A. Lleo, G. Raimondo, T. Ruggiero, Simona Marenco, Valeria Pace Palitti, G.B. Gaeta, Stefania Paolucci, and Ilaria Lenci

Subjects
Hepatology, Resistance (ecology), business.industry, Genotype, Medicine, business, Virology
Published
2018

33. Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy

Author

D. Masci, P. Sammarco, M. Andreoni, Elisabetta Teti, Francesca Ceccherini Silberstein, C.F. Perno, Luca Foroghi, M. Compagno, Vincenzo Malagnino, A. Gentile, Cesare Sarrecchia, M. Patti, L. Sarmati, M. Barra, B. Coladarce, G. Rodoquino, R.A. Cavasio, Valeria Cento, C. Stingone, E. Rossi, L. Coppola, and G. Malerba

Subjects
Drug, medicine.medical_specialty, Hepatology, business.industry, media_common.quotation_subject, 030204 cardiovascular system & hematology, DIRECT ACTING ANTIVIRALS, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Family medicine, Cohort, medicine, business, media_common
Published
2018

34. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?

Author

Angelico Mario, Ilaria Lenci, Valeria Micheli, L. Sarmati, Giuliano Rizzardini, C.F. Perno, M. Andreoni, Guido Gubertini, Elisabetta Teti, Simona Francioso, Francesca Ceccherini Silberstein, Valeria Cento, Monica Schiavini, Marco Ciotti, C. Masetti, Simone Passerini, Carlo Magni, Marianna Aragri, V.C. Di Maio, Aldo Bertoli, and Martina Milana

Subjects
Hepatology, business.industry, In real life, Medicine, business, Virology, Direct acting
Published
2018

35. Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection

Author

A. Battisti, Olympia E. Anastasiou, Giuseppe Maria De Sanctis, Lavinia Fabeni, Caterina Pasquazzi, L. Carioti, Patrick T F Kennedy, Domenico Di Carlo, T. Mari, Jens Verheyen, Sandro Grelli, V. Svicher, Mario Angelico, J. Vecchiet, R. Salpini, M. Andreoni, L. Sarmati, Luna Colagrossi, A. Iuvara, Marianna Aragri, M. Lichtner, Giustino Parruti, Massimo Marignani, Aldo Bertoli, L. Piermatteo, V. Fini, Carlotta Cerva, U.S. Gill, Claudio Maria Mastroianni, Francesca Ceccherini Silberstein, P. Maurizio, C.F. Perno, Vincenzo Malagnino, and N. Iapadre

Subjects
HBsAg, Hepatology, Hbeag negative, C-terminus, Medizin, Hbv genotype, Biology, Affect (psychology), Virology
Published
2018

36. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

Author

V. Boccaccio, Irene Maida, Ennio Polilli, Alessandro Ciaccio, Ilaria Lenci, Anna Claudia Pellicelli, Marilena Rendina, Fabio Niero, Guido Gubertini, Mario Angelico, T. Ruggiero, Stefano Bonora, Barbara Rossetti, Caterina Pasquazzi, Niccolò Gabriele Coppola, Simona Francioso, Silvia Barbaliscia, M. Puoti, M. Andreoni, L. Foroghi, L. Sarmati, Silvia Paolucci, Giuliana Fiorentino, Teresa Pollicino, G.B. Gaeta, C.F. Perno, Giustino Parruti, Valeria Cento, Laura Ambra Nicolini, Gloria Taliani, Elisabetta Teti, Lucio Boglione, Asia Bertoli, Sergio Babudieri, Valeria Micheli, Renato Maserati, Marianna Aragri, F. Ceccherini-Silberstein, Vincenzo Vullo, A. R. D’Ambrosio, Simona Marenco, A. Lleo, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Vincenzo Sangiovanni, Maurizio Zazzi, Vincenza Calvaruso, Alessia Ciancio, V. Pace Palitti, Bianca Bruzzone, and Giacomo Raimondo

Subjects
Hepatology, business.industry, Gastroenterology, Medicine, business, Virology
Published
2018

37. A close monitoring of virological and immunological hepatitis B markers can improve the diagnosis of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases

Author

R. Salpini, M. Andreoni, C.F. Perno, A. Battisti, L. Piermatteo, F. Ceccherini-Silberstein, William Arcese, M.L. Cantonetti, V. Svicher, A. Sacco, Vincenzo Malagnino, Carlotta Cerva, and L. Sarmati

Subjects
Anti hbc, Hbsag negative, Hepatology, business.industry, Gastroenterology, medicine, Hbv reactivation, Hepatitis B, medicine.disease, business, Virology
Published
2019

38. GENDER DIFFERENCES IN HCV CHRONIC LIVER DISEASE: A REAL LIFE EVALUATION IN PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) COHORT STUDY

Author

M. Puoti, G.B. Gaeta, T. Santantonio, Francesco Paolo Russo, Silvia Fargion, M. Siciliano, M. Di Gregorio, Salvatore Madonia, Pierluigi Toniutto, D. Ieluzzi, Loredana Falzano, Giuseppe Montalto, Luchino Chessa, Giuseppe Foti, Adriano Lazzarin, Gianpiero D'Offizi, Carmine Coppola, Gloria Taliani, Claudio Viscoli, Massimo Zuin, Maria Rendina, Antonio Craxì, Al Zignego, Giovanni Raimondo, V. De Maria, E.M. Erne, Mario Strazzabosco, Adele Giammario, M. Colombo, P. Andreone, Claudio Maria Mastroianni, Alessandro Federico, G. Angarano, Andrea Giacometti, Maria Cristina Vinci, Antonio Benedetti, Carlo Ferrari, Erica Villa, Floriano Rosina, Marcello Persico, G. Nardone, Marco Massari, M. Rumi, Liliana Chemello, Gabriella Verucchi, Ivan Gentile, M.G. Quaranta, Loreta A. Kondili, Guglielmo Borgia, M. Andreoni, Stefano Vella, Antonio Gasbarrini, Maurizia Rossana Brunetto, Pierluigi Blanc, Alessia Ciancio, Alfredo Alberti, Carlo Torti, A. Di Leo, Nicola Caporaso, Kondili, L, Quaranta, Mg, Falzano, L, Di Gregorio, M, Brunetto, M, Zignego, Al, Ciancio, A, Di Leo, A, Rendina, M, Raimondo, G, Ferrari, C, Craxi, A, Taliani, G, Borgia, Guglielmo, Gentile, Ivan, Santantonio, Ta, Giammario, A, Blanc, P, Gaeta, Gb, Gasbarrini, A, Siciliano, M, Chessa, L, Erne, Em, Ieluzzi, D, Russo, Fp, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Alberti, A, Puoti, M, Nardone, G, De Maria, V, Massari, M, Montalto, G, Foti, G, Rumi, Mg, Giacometti, A, Benedetti, A, D'Offizi, G, Strazzabosco, M, Fargion, S, Angarano, G, Federico, A, Caporaso, Nicola, Mastroianni, C, Toniutto, P, Colombo, M, Lazzarin, A, Torti, C, Andreoni, M, Rosina, F, Viscoli, C, Vella, S, and Villa, E.

Subjects
030203 arthritis & rheumatology, medicine.medical_specialty, Hepatology, business.industry, Chronic liver disease, medicine.disease, Surgery, 03 medical and health sciences, 0302 clinical medicine, Life evaluation, Internal medicine, medicine, 030211 gastroenterology & hepatology, business, Studio, Cohort study
Published
2016

39. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment

Author

A. Manunta, A. Grieco, Lorenzo Nosotti, D. Di Paolo, Gloria Taliani, Umberto Vespasiani Gentilucci, Carlo Magni, L. Lambiase, Simona Landonio, M. Tontodonati, A. Di Biagio, C.F. Perno, F.P. Antonucci, Gabriella d'Ettorre, Valeria Cento, S. Grieco, Maria Stella Mura, Francesca Ceccherini Silberstein, Cesare Sarrecchia, Dante Romagnoli, Elisabetta Teti, Laura Gianserra, Miriam Lichtner, Giustino Parruti, Aldo Bertoli, F. De Leonardis, Adriano M. Pellicelli, P. Cacciatore, Claudio Maria Mastroianni, Laura Ambra Nicolini, M. Andreoni, Antonio Gasbarrini, Simona Francioso, Sergio Babudieri, Simona Marenco, J. Vecchiet, Martina Milana, Mario Angelico, Caterina Pasquazzi, Ivana Maida, Ilaria Lenci, Valeria Micheli, Antonio Picciotto, Marianna Aragri, Marco Romano, E. D’Amico, Giuliano Rizzardini, Filomena Morisco, V.C. Di Maio, M. Siciliano, Savino Bruno, Marco Ciotti, and M. Puoti

Subjects
Genetics, 03 medical and health sciences, PRECLINICAL CHARACTERISATION OF JNJ-54257099 – A POTENT URIDINE-BASED NUCLEOTIDE POLYMERASE INHIBITOR IN PHASE I CLINICAL DEVELOPMENT FOR THE TREATMENT OF CHRONIC HEPATITIS C, 0302 clinical medicine, Hepatology, 030220 oncology & carcinogenesis, Genotype, 030211 gastroenterology & hepatology, Biology, Direct acting
Published
2016

40. A Prospective Study Showing an Excellent Response of Patients with Low-Risk Differentiated Thyroid Cancer Who Did Not Undergo Radioiodine Remnant Ablation after Total Thyroidectomy

Author

M. Conceicao O. C. Mamone, Rosalia P. Padovani, Rui M. B. Maciel, Elza S. Ikejiri, Danielle M. Andreoni, Carolina Castro Porto Silva Janovsky, Ji H. Yang, Rosa Paula M. Biscolla, Eduardo Z. Malouf, Cleber P. Camacho, Cláudia C. D. Nakabashi, and Jairo Wagner

Subjects
Total thyroidectomy, medicine.medical_specialty, Clinical Thyroidology / Original Paper, business.industry, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Urology, Remnant ablation, 030209 endocrinology & metabolism, medicine.disease, Surgery, Thyroid carcinoma, 03 medical and health sciences, Neck ultrasound, 0302 clinical medicine, 030220 oncology & carcinogenesis, Medicine, Thyroglobulin, Radioactive iodine, business, Prospective cohort study, Thyroid cancer
Abstract

To prospectively evaluate the outcome of patients with low-risk papillary thyroid carcinoma treated with total thyroidectomy (TT) who did not undergo radioiodine remnant ablation (RRA).We prospectively followed up 57 patients; 3 months after TT, thyroglobulin (Tg) assessment and neck ultrasonography (US) were performed while patients were taking l-T4, presenting suppressed TSH. Six months after TT, patients underwent stimulated Tg testing and whole-body scan (WBS) after recombinant TSH (rhTSH). Then, 18 months after TT, the patients were evaluated by neck US and Tg under TSH between 0.5 and 2.0 mIU/ml. Two years after TT, we performed another rhTSH assessment, measuring Tg and making a WBS. The patients were then annually monitored with neck US and Tg measurement under TSH between 0.5 and 2.0 mIU/l for 36-84 months.Neck US of all patients, 3 months after TT, presented no evidence of abnormal residual tissues or metastatic lymph nodes (negative neck US); at this time, the mean Tg level was 0.42 ng/ml. Six months after surgery, after rhTSH, the mean thyroid bed uptake was 1.82%, and Tg levels ranged from 0.10 to 22.30 ng/ml (mean, 2.89 ng/ml). The patients were followed up without any sign of recurrence (negative neck US and stable or decreasing Tg levels). During the ongoing follow-up, the Tg trend was stable or decreasing, independently of the initial suppressed or stimulated Tg level, or WBS uptake.In patients with low-risk differentiated thyroid cancer, who were operated by TT and who did not undergo RRA, an excellent response to treatment may be confirmed by annual neck US and Tg trend.

Published
2015

42. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

Author

V.C. Di Maio, S. Barbaliscia, I. Lenci, E. Teti, F.P. Antonucci, V. Cento, M. Aragri, S. Paolucci, B. Bruzzone, N. Coppola, T. Ruggiero, T. Pollicino, E. Polilli, C. Pasquazzi, V. Pace Palitti, C.F. Magni, V. Micheli, A. Di Biagio, L. Sticchi, M. Melis, S. Francioso, C. Masetti, L. Foroghi, C. Sarrecchia, L. Baiocchi, S. Landonio, A. Bertoli, V. Calvaruso, F. Morisco, I. Maida, S. Marenco, A. Leo, V. Ghisetti, A. Ciancio, P. Sacchi, S. Novati, G. Brancaccio, A. Pieri, M. Puoti, P. Toniutto, V. Vullo, A. Aghemo, G. Di Perri, S. Babudieri, G. Rizzardini, S. Bruno, A. Pellicelli, G. Taliani, G. Raimondo, F. Baldanti, G.B. Gaeta, A. Craxì, G. Parruti, M. Andreoni, M. Angelico, C.F. Perno, and F. Ceccherini-Silberstein

Subjects
Hepatology, Resistance (ecology), business.industry, Gastroenterology, Medicine, business, Virology
Published
2017

43. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

Author

Ilaria Lenci, A. Di Biagio, Giuliano Rizzardini, L. Marinaro, C. D'Ambrosio, Fausto Baldanti, Ivana Maida, G.B. Gaeta, M. Puoti, T. Ruggiero, Mario Angelico, Vincenza Calvaruso, Laura Sticchi, Mario Starace, Giustino Parruti, P. Cacciatore, Nicola Caporaso, Caterina Pasquazzi, Stefania Paolucci, Anna Claudia Pellicelli, M. Andreoni, C. Masetti, Sergio Babudieri, Gabriella d'Ettorre, Francesco Santopaolo, Raffaele Cozzolongo, P. Andreone, Carlo Magni, Valeria Cento, Guido Gubertini, J. Vecchiet, Stefano Novati, Nicola Coppola, C.F. Perno, Bianca Bruzzone, F. De Leonardis, V. Pace Palitti, Marianna Aragri, A. Grieco, Pierluigi Tarquini, G. De Stefano, G. Raimondo, Teresa Pollicino, Alessia Giorgini, Giorgio Barbarini, Valeria Ghisetti, G. Verucchi, M.C. Sorbo, Savino Bruno, M. Paoloni, F. Ceccherini-Silberstein, Roberto Gulminetti, Antonio Craxì, Filomena Morisco, Manuela Merli, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Simona Francioso, Simona Landonio, Aldo Bertoli, A. Mancon, Valeria Micheli, Antonio Picciotto, V. Boccaccio, M. Melis, Ennio Polilli, F.P. Antonucci, Dante Romagnoli, and Silvia Barbaliscia

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Interferon free, Gastroenterology, DIRECT ACTING ANTIVIRALS, 03 medical and health sciences, 0302 clinical medicine, Second line, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In real life, 030211 gastroenterology & hepatology, business
Published
2017

44. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies

Author

A. Grieco, Valeria Cento, Savino Bruno, M. Paoloni, Anna Claudia Pellicelli, Gabriella d'Ettorre, Raffaele Cozzolongo, G.D. Stefano, Carlo Magni, V. Boccaccio, M. Andreoni, Fausto Baldanti, Silvia Barbaliscia, J. Vecchiet, Valeria Micheli, Antonio Picciotto, Giustino Parruti, Guido Gubertini, M. Melis, Pierluigi Tarquini, Francesca Ceccherini-Silberstein, Bianca Bruzzone, Sergio Babudieri, Antonio Di Biagio, M. Puoti, Manuela Merli, L. Marinaro, Mario Starace, Caterina Pasquazzi, Marianna Aragri, Antonio Craxì, Teresa Pollicino, Filomena Morisco, V.C. Di Maio, Alessia Giorgini, Vincenzo Sangiovanni, Giorgio Barbarini, Valeria Ghisetti, G. Verucchi, T. Ruggiero, Ivana Maida, P. Andreone, Vincenza Calvaruso, Giovanni Raimondo, C. D'Ambrosio, Simona Francioso, F.P. Antonucci, Dante Romagnoli, C.F. Perno, Mario Angelico, Ilaria Lenci, Alessia Ciancio, Roberto Gulminetti, G.B. Gaeta, Simona Landonio, Nicola Caporaso, Francesco Santopaolo, Nicola Coppola, Laura Sticchi, Valeria Pace Palitti, Stefania Paolucci, Aldo Bertoli, and A. Mancon

Subjects
0301 basic medicine, Hepatology, business.industry, Hepatitis C virus, Interferon free, medicine.disease_cause, DIRECT ACTING ANTIVIRALS, Virology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Second line, medicine, In real life, 030211 gastroenterology & hepatology, business
Published
2017

45. HBV-HDV co-infection constrains HBV genetic evolution in HBsAg

Author

A. Battisti, E. Nebuloso, L. Sarmati, Maria Stanzione, V. Svicher, G. De Sanctis, Mario Angelico, Nicola Coppola, Giuseppina Cappiello, R. Salpini, Michela Pollicita, Alberto Spanò, Luna Colagrossi, Aldo Bertoli, Pascale Trimoulet, Carmine Minichini, Caterina Pasquazzi, A. Barlattani, Ilaria Lenci, R. Longo, Leonardo Baiocchi, Claudio Maria Mastroianni, Rossana Scutari, C.F. Perno, M. Andreoni, T. Mari, Vincenzo Malagnino, Alfonso Galeota Lanza, G. Stornaiuolo, Massimo Marignani, Miriam Lichtner, Hervé Fleury, and N. Iapadre

Subjects
not available, HBsAg, Hepatology, business.industry, Genetic Evolution, Gastroenterology, Medicine, Biology, business, Virology, Co infection
Published
2016

46. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

Author

Carlo Magni, Francesca Ceccherini-Silberstein, M. Puoti, Claudio Maria Mastroianni, A. Di Biagio, Marco Romano, Filomena Morisco, Giustino Parruti, Antonio Gasbarrini, Gloria Taliani, M. Siciliano, Simona Landonio, V.C. Di Maio, Martina Milana, Laura Gianserra, F. Deodati, Caterina Pasquazzi, M. Andreoni, J. Vecchiet, Valeria Cento, L. Lambiase, Marianna Aragri, Simona Francioso, E. D’Amico, Gabriella d'Ettorre, Giuliano Rizzardini, D. Di Paolo, Antonio Grieco, F. De Leonardis, A. Manunta, Ivana Maida, Anna Claudia Pellicelli, Mario Angelico, K. Yu La Rosa, Miriam Lichtner, P. Cacciatore, Cesare Sarrecchia, F.P. Antonucci, Aldo Bertoli, Valeria Micheli, Antonio Picciotto, Dante Romagnoli, Savino Bruno, Laura Ambra Nicolini, Ilaria Lenci, C.F. Perno, Marco Ciotti, Lorenzo Nosotti, Simona Marenco, Elisabetta Teti, M. Tontodonati, Maria Stella Mura, R. Campoli, Nicola Caporaso, S. Grieco, Sergio Babudieri, and Umberto Vespasiani-Gentilucci

Subjects
Genetics, chemistry.chemical_compound, NS3, Hepatology, chemistry, Direct sequencing, Genotype, Gastroenterology, Clinical significance, Biology, NS5A, NS5B, Direct acting
Published
2016

47. Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies

Author

C.F. Perno, Giuliano Rizzardini, Elisa Biliotti, Carlo Magni, Paolo Casalino, M. Melis, Laura Gianserra, D. Di Paolo, F. Ceccherini-Silberstein, Ilaria Lenci, Elena Danieli, Giustino Parruti, Ennio Polilli, Elisabetta Teti, Sergio Babudieri, Mario Angelico, Gloria Taliani, Erica Villa, Jeremie Guedj, M. Andreoni, Tiziana Quirino, Roberta Alfieri, A. Di Biagio, A. D’A. Monforte, M. Siciliano, Valeria Micheli, Sergio Bernardini, Caterina Pasquazzi, Barbara Menzaghi, Valeria Cento, Domenico Di Carlo, L. Sarmati, F.P. Antonucci, Dante Romagnoli, Laura Ambra Nicolini, Vincenza Calvaruso, Thi Huyen Tram Nguyen, Maddalena Cerrone, Antonio Craxì, M. Puoti, and V.C. Di Maio

Subjects
Normalization (statistics), Hepatology, Interferon, business.industry, Biphasic kinetics, medicine, Pharmacology, business, medicine.drug
Published
2016

48. Economic Evaluation for The Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) From The NHS Perspective: A Spending Predictor Model for Italy, Romania and Spain

Author

Jaime Espín, Raffaella Viti, P. Horcajada Gallego, Adrian Pana, FS Mennini, Andrea Marcellusi, Loredana Sarmati, Giampiero Favato, M. Andreoni, and A Streinu Cercel

Subjects
medicine.medical_specialty, business.industry, Health Policy, Family medicine, Perspective (graphical), Economic evaluation, Public Health, Environmental and Occupational Health, Skin structure, medicine, business, Surgery
Published
2017

49. Natural HCV resistance is common in Italy and differently associated to genotypes

Author

Simona Landonio, Barbara Menzaghi, Giustino Parruti, T. Ruggiero, Valeria Cento, Francesca Ceccherini-Silberstein, Ilaria Lenci, M. Melis, Giuliano Rizzardini, Antonio Gasbarrini, P. Cacciatore, V. Pace Palitti, M.C. Sorbo, Ennio Polilli, Martina Milana, Alessandro Pieri, Laura Gianserra, Anna Claudia Pellicelli, P. Andreone, C. Masetti, Bianca Bruzzone, Simona Marenco, Elisabetta Teti, M. Andreoni, Gloria Taliani, Aldo Bertoli, Elisa Biliotti, Miriam Lichtner, Nicola Coppola, Vincenza Calvaruso, Fausto Baldanti, Stefania Paolucci, C.F. Perno, Carlo Magni, Sergio Babudieri, Valeria Micheli, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Dante Romagnoli, Laura Ambra Nicolini, Mario Angelico, Loredana Sarmati, M. Siciliano, M. Puoti, N. Iapadre, Marianna Aragri, Vincenzo Vullo, Caterina Pasquazzi, and F. De Leonardis

Subjects
0301 basic medicine, Genetics, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Hepatology, Resistance (ecology), business.industry, Genotype, Gastroenterology, Medicine, 030211 gastroenterology & hepatology, business
Published
2017

50. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

Author

V. Cento, S. Barbaliscia, I. Lenci, T. Ruggiero, C. Masetti, C.F. Magni, V. Micheli, S. Paolucci, Y. Troshina, E. Biliotti, M. Milana, M. Melis, E. Teti, L. Lambiase, B. Menzaghi, L.A. Nicolini, S. Marenco, V.C. Di Maio, M. Aragri, A. Pecchioli, A. Bertoli, F.P. Antonucci, L. Sarmati, C. Sarrecchia, M. Macera, N. Coppola, E. Danieli, D. Romagnoli, A. Pellicelli, S. Bonora, S. Babudieri, A. Di Biagio, A. Picciotto, S. Novati, M. Siciliano, V. Messina, E. Claar, F. Baldanti, C. Pasquazzi, A. Ciancio, M. Puoti, V. Ghisetti, M. Andreoni, G. Taliani, G. Rizzardini, M. Angelico, C.F. Perno, and F. Ceccherini-Silberstein

Subjects
Resistance test, Protease, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, medicine, In real life, Pharmacology, business
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results